Intestinal LPC/LPA modulation of gut microbiota and metabolic disease
肠道 LPC/LPA 对肠道微生物群和代谢疾病的调节
基本信息
- 批准号:9354489
- 负责人:
- 金额:$ 35.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-20 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AblationAdultAdverse effectsAtherosclerosisBacteroidetesCardiovascular DiseasesCardiovascular systemChildCholineChronicClinicalClinical DataConsequentialismConsumptionDataDevelopmentDiabetes MellitusDietDyslipidemiasEffectivenessEnzymesEsterificationFatty LiverFatty acid glycerol estersGastrectomyGastrointestinal tract structureGenesGenetic VariationGoalsHigh Fat DietHydrolysisHyperglycemiaHyperlipidemiaInbred Strains MiceIncidenceIndividualInterventionIntestinesKnowledgeLipidsLipolysisLiver diseasesLysophosphatidylcholinesLysophospholipidsMediatingMetabolicMetabolic DiseasesMorbid ObesityMusNutrientObesityOperative Surgical ProceduresPancreasPharmacologyPhenocopyPhospholipase A2Phospholipid MetabolismPhospholipidsPlasmaPopulation HeterogeneityPrevalenceProceduresProductionReportingResistanceRiskRoleTestingTherapeuticUnited StatesWorkYouthbariatric surgerybasediabetes managementdisorder riskexperimental studyfeedingglucose tolerancegut microbiotaimprovedlysophosphatidic acidmicrobiomemicrobiotamouse modelnovelnovel strategiesnovel therapeuticspandemic diseasepre-clinicalpublic health relevanceresponsetherapeutic target
项目摘要
PROJECT SUMMARY/ABSTRACT
Incidence of obesity continues to escalate in recent years with increasing consumption of high fat meals,
leading to significant increase in risk and incidence of metabolic diseases including diabetes and cardiovascular
disease. The current strategy for obesity/diabetes management is not optimal with bariatric surgery being the
most effective. However, the potential risk of surgical procedures has limited its use to clinically severe obese
individuals. Therefore, the development of novel therapeutics that can mimic the metabolic benefits of bariatric
surgery is highly desirable. Our earlier studies revealed that inactivation of the group 1b phospholipase A2
(PLA2g1b) gene in mice resulted in metabolic benefits similar to that observed with bariatric surgery, including
resistance to high fat diet (HFD)-induced obesity, improved glucose tolerance to alleviate hyperglycemia, and
resistance to HFD-induced dyslipidemia. Additional studies revealed that the gut microbiota of Pla2g1b-/- mice
also resembled those present in mice with vertical sleeve gastrectomy (VSG) surgery, with both procedures
suppressing HFD-induced increase of Firmicutes/Bacteroidetes ratio in the gut microbiota. Interestingly, we also
observed significant reduction of PLA2g1b lipolytic products, lysophospholipids (LPC) and lysophosphatidic acid
(LPA)/choline, in plasma and along the intestinal tract of mice after VSG surgery. These results indicated that
PLA2g1b inactivation and VSG surgery phenocopy each other , with both procedures reducing LPC/LPA/choline
levels and altering the gut microbiota to confer metabolic benefits. These data provided strong support for the
premise that PLA2g1b inhibition may be a novel therapeutic strategy to recapitulate the metabolic benefits of
bariatric surgery. The overall goals of this project are: (i) to identify the mechanism underlying the inter-
relationship between PLA2g1b inactivation and bariatric surgery in modulation of the gut microbiota and
metabolic disease risk, and (ii) test the hypothesis that pharmacologic PLA2g1b inhibition is a viable strategy for
metabolic disease intervention. Aim 1 will test the hypothesis that lipid nutrient metabolites generated by
PLA2g1b hydrolysis of luminal phospholipids are responsible for the altered gut microbiota in response to HFD.
This aim will identify the specific influence of LPC, LPA, and/or choline in dictating the gut microbiota and
metabolic disease risk. Aim 2 will identify the mechanism underlying the sustained metabolic benefits of VSG
surgery. This aim will test the hypothesis that VSG surgery elevates intestinal expression of the LPC re-
esterification enzyme LPCAT3 to reduce intestinal LPC/LPA/choline levels with the accompanying metabolic
benefits. Aim 3 will test the hypothesis that PLA2g1b inhibition reprograms the gut microbiota to reverse and
improve obesity and diabetes. A segregating panel of 8 genetically diverse inbred mouse strains will be used to
evaluate the effectiveness of PLA2g1b inhibition for obesity/diabetes intervention in a genetically diverse
population. Completion of this study will fill a knowledge gap regarding how dietary nutrients modulate the gut
microbiota and how modulating nutrient processing in the digestive tract may confer metabolic benefits.
项目摘要/摘要
近年来,随着高脂肪饮食的消费增加,肥胖症的发病率持续上升,
导致包括糖尿病和心血管在内的代谢性疾病的风险和发病率显著增加
疾病。目前的肥胖/糖尿病管理策略并不是最优的,因为减肥手术是
最有效的。然而,外科手术的潜在风险使其仅限于临床上严重的肥胖症。
个人。因此,能够模拟减肥的代谢益处的新疗法的开发
手术是非常可取的。我们早期的研究表明,1b组磷脂酶A2的失活
(PLA2g1b)基因在小鼠中产生的代谢益处与减肥手术中观察到的相似,包括
抵抗高脂饮食(HFD)诱导的肥胖,改善葡萄糖耐量以缓解高血糖,以及
对高脂血症的抵抗力。进一步的研究表明,Pla2g1b-/-小鼠的肠道微生物区系
也类似于接受垂直袖状胃切除(VSG)手术的小鼠,这两种手术都是
抑制HFD引起的肠道微生物区系中Firmicuts/类杆菌比例的增加。有趣的是,我们还
观察到PLA2g1b脂解产物、溶血磷脂(LPC)和溶血磷脂酸显著减少
(LPA)/胆碱,在VSG术后小鼠的血浆和肠道中。这些结果表明,
PLA2g1b失活和VSG手术表型相互作用,两种方法都降低了LPC/LPA/胆碱
水平和改变肠道微生物区系以赋予新陈代谢益处。这些数据为经济增长提供了有力支持。
假设PLA2g1b抑制可能是一种新的治疗策略,概括了
减肥手术。这一项目的总体目标是:(1)确定相互关系的基础机制
PLA2g1b失活与减肥手术对肠道微生物区系调控的关系
代谢性疾病风险,以及(Ii)检验药物抑制PLA2g1b是一种可行的策略的假设
代谢性疾病干预。目标1将检验这样一种假设,即由
腔磷脂PLA2g1b的水解是HFD引起肠道微生物区系改变的原因。
这一目标将确定LPC、LPA和/或胆碱在决定肠道微生物区系和
代谢性疾病风险。目标2将确定VSG持续代谢益处的潜在机制
做手术。这一目标将检验这样的假设,即VSG手术提高了肠道LPC Re-1的表达。
酯化酶LPCAT3降低肠道LPC/LPA/胆碱水平及其代谢
福利。目标3将测试假设,PLA2g1b抑制重新编程肠道微生物区系,以逆转和
改善肥胖和糖尿病。一个由8个遗传不同的近交系小鼠品系组成的分离小组将用于
评价PLA2g1b抑制对肥胖/糖尿病干预的遗传多样性的有效性
人口。这项研究的完成将填补关于饮食营养如何调节肠道的知识空白。
微生物区系,以及如何调节消化道中的营养处理可以赋予新陈代谢益处。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Yiu-Kwan Hui其他文献
David Yiu-Kwan Hui的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Yiu-Kwan Hui', 18)}}的其他基金
Polymorphic ApoE at the crossroad of lipid metabolism and inflammation in atherosclerosis
多态性 ApoE 处于动脉粥样硬化脂质代谢和炎症十字路口
- 批准号:
10533337 - 财政年份:2021
- 资助金额:
$ 35.89万 - 项目类别:
Polymorphic ApoE at the crossroad of lipid metabolism and inflammation in atherosclerosis
多态性 ApoE 处于动脉粥样硬化脂质代谢和炎症十字路口
- 批准号:
10363587 - 财政年份:2021
- 资助金额:
$ 35.89万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
10167112 - 财政年份:2020
- 资助金额:
$ 35.89万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
10582114 - 财政年份:2019
- 资助金额:
$ 35.89万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
9761773 - 财政年份:2019
- 资助金额:
$ 35.89万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
10375435 - 财政年份:2019
- 资助金额:
$ 35.89万 - 项目类别:
ApoE receptor-2 in vascular disease progression and regression
ApoE 受体 2 在血管疾病进展和消退中的作用
- 批准号:
9889159 - 财政年份:2019
- 资助金额:
$ 35.89万 - 项目类别:
Role of Endothelial and Macrophage ApoER2 in Atherosclerosis Modulation
内皮细胞和巨噬细胞 ApoER2 在动脉粥样硬化调节中的作用
- 批准号:
9211369 - 财政年份:2014
- 资助金额:
$ 35.89万 - 项目类别:
Role of Endothelial and Macrophage ApoER2 in Atherosclerosis Modulation
内皮细胞和巨噬细胞 ApoER2 在动脉粥样硬化调节中的作用
- 批准号:
8794465 - 财政年份:2014
- 资助金额:
$ 35.89万 - 项目类别:
Role of Endothelial and Macrophage ApoER2 in Atherosclerosis Modulation
内皮细胞和巨噬细胞 ApoER2 在动脉粥样硬化调节中的作用
- 批准号:
8998064 - 财政年份:2014
- 资助金额:
$ 35.89万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 35.89万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 35.89万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 35.89万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 35.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 35.89万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 35.89万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 35.89万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 35.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 35.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 35.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)